{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=39",
    "query": {
      "condition": "Skin Disorder",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 16122,
    "total_pages": 1613,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T21:51:48.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01663727",
      "title": "Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab [Avastin]",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 481,
      "start_date": "2012-08-27",
      "completion_date": "2017-11-21",
      "has_results": true,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Glendora",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663727"
    },
    {
      "nct_id": "NCT00896727",
      "title": "S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "fluorescent antibody technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2100,
      "start_date": "2006-07-17",
      "completion_date": "2009-04-02",
      "has_results": false,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896727"
    },
    {
      "nct_id": "NCT02390427",
      "title": "Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nancy Lin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2015-04-20",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02390427"
    },
    {
      "nct_id": "NCT04127318",
      "title": "Low-moderate Intensity Pedaling During Immunotherapy Administration",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer of Skin",
        "Cancer of Kidney",
        "Cancer of Bladder",
        "Exercise, Aerobic",
        "Immunotherapy"
      ],
      "interventions": [
        {
          "name": "Pedaling Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01-31",
      "completion_date": "2020-10",
      "has_results": false,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04127318"
    },
    {
      "nct_id": "NCT02498613",
      "title": "A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Small Cell Carcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Lung Non-Small Cell Cancer AJCC v7",
        "Stage III Lung Small Cell Carcinoma AJCC v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIA Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIA Lung Small Cell Carcinoma AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIB Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIB Lung Small Cell Carcinoma AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7",
        "Stage IV Lung Small Cell Carcinoma AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Lung Small Cell Carcinoma",
        "Unresectable Pancreatic Adenocarcinoma",
        "Unresectable Pancreatic Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "18F-Fluoromisonidazole",
          "type": "OTHER"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2016-08-31",
      "completion_date": "2027-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498613"
    },
    {
      "nct_id": "NCT06315296",
      "title": "An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Breast Carcinoma",
        "Metastatic Lung Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Behavioral Dietary Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Text Message-Based Navigation Intervention",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Dietary Counseling and Surveillance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Neurocognitive Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-12-13",
      "completion_date": "2025-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06315296"
    },
    {
      "nct_id": "NCT01736670",
      "title": "An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Steroid Responsive Dermatoses",
        "Chronic Steroid Responsive Dermatoses"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide spray",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone acetonide cream",
          "type": "DRUG"
        },
        {
          "name": "Alcohol spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patel, Rita Vikram, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-12-04",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736670"
    },
    {
      "nct_id": "NCT03929783",
      "title": "Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Contrast Enhanced Digital Mammography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 80 Years · Female only"
      },
      "enrollment_count": 107,
      "start_date": "2020-06-23",
      "completion_date": "2023-01-27",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03929783"
    },
    {
      "nct_id": "NCT00651417",
      "title": "Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Localized Breast Cancer",
        "Localized Prostate Cancer",
        "Patients Receiving External Beam Radiotherapy"
      ],
      "interventions": [
        {
          "name": "Organic Germanium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Arizona Oncology Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2005-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-23",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651417"
    },
    {
      "nct_id": "NCT02431260",
      "title": "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors and Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "INCB054329 Monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2015-04-14",
      "completion_date": "2018-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-06-14",
      "last_synced_at": "2026-10-30T21:51:48.956Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431260"
    }
  ]
}